Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16915478 | 1.00 | RAB9A (0.55) | RAB9ANPC1KDM4EGAAMAPT | |
| SCHEMBL19076160 | 0.83 | NPC1 (0.74) | RAB9ANPC1KDM4EGAAMAPT | |
| SCHEMBL16915450 | 0.81 | KMT2A (0.47) | RAB9ANPC1KDM4EGAAMAPT | |
| SCHEMBL16915451 | 0.81 | KMT2A (0.47) | RAB9ANPC1KDM4EGAAMAPT | |
| SCHEMBL23743152 | 0.81 | CYP1A1 (0.63) | KDM4EMAPTMAPK1NFE2L2CYP1A1 | |
| SCHEMBL11634272 | 0.81 | RAB9A (0.41) | RAB9ANPC1KDM4EGAAMAPT | |
| SCHEMBL11634270 | 0.81 | RAB9A (0.41) | RAB9ANPC1KDM4EGAAMAPT | |
| SCHEMBL11633305 | 0.80 | CHRNB2 (0.47) | RAB9ANPC1KDM4EGAAMAPT | |
| SCHEMBL11633301 | 0.80 | CHRNB2 (0.47) | RAB9ANPC1KDM4EGAAMAPT | |
| SCHEMBL19076267 | 0.79 | NFE2L2 (0.53) | RAB9ANPC1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326122-A1 | Anti-Angiogenic Compounds | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-11-10 | — | — | US | claimed |
| US-10300155-B2 | Alpha-synuclein ligands | WASHINGTON UNIVERSITY (US) | 2019-05-28 | — | — | US | disclosed |
| US-9975860-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2018-05-22 | — | — | US | disclosed |
| US-9975860-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2018-05-22 | — | — | US | disclosed |
| US-9975860-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2018-05-22 | — | — | US | disclosed |
| US-20170189566-A1 | ALPHA-SYNUCLEIN LIGANDS | WASHINGTON UNIVERSITY (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189566-A1 | ALPHA-SYNUCLEIN LIGANDS | WASHINGTON UNIVERSITY (US) | 2017-07-06 | — | — | US | disclosed |
| EP-3094625-A1 | ANTI-ANGIOGENIC COMPOUNDS | University College Dublin National University Of Ireland, Dublin (IE) | 2016-11-23 | — | — | EP | disclosed |
| US-20160326122-A1 | Anti-Angiogenic Compounds | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326122-A1 | Anti-Angiogenic Compounds | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326122-A1 | Anti-Angiogenic Compounds | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-11-10 | — | — | US | disclosed |
| WO-2015107122-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300155-B2 | Alpha-synuclein ligands | SNCA, PARK7, LRRK2 | RAB9A 152/4885NPC1 382/4885KDM4E 4649/4885 |
| US-20160326122-A1 | Anti-Angiogenic Compounds | VEGFA, FLT4, FLT1 | RAB9A 1177/4885NPC1 3155/4885KDM4E 4170/4885 |
| US-20170189566-A1 | ALPHA-SYNUCLEIN LIGANDS | SNCA, PARK7, LRRK2 | RAB9A 152/4885NPC1 382/4885KDM4E 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.